BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS
Clinical trials for BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS explained in plain language.
Never miss a new study
Get alerted when new BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS trials appear
Sign up with your email to follow new studies for BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug combo offers hope for Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial is testing a chemotherapy drug called CPX-351 in people with high-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) that came back or didn't respond to standard treatment. The goal is to find the best dose that is safe and to se…
Matched conditions: BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Second chance: vyxeos targets tough leukemia after standard chemo fails
Disease control Recruiting nowThis study tests a drug called Vyxeos in adults with acute myeloid leukemia (AML) whose cancer did not go away after standard chemotherapy. Vyxeos combines two chemo drugs inside a tiny fat bubble (liposome) to deliver them more effectively. The trial will check for side effects …
Matched conditions: BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS
Phase: PHASE1, PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for rare blood disorder: drug targets overactive immune cells
Disease control Recruiting nowThis phase 2 trial is testing the drug ruxolitinib in people with hypereosinophilic syndrome, a rare condition where the body produces too many eosinophils (a type of white blood cell), causing organ damage. The study aims to see if ruxolitinib can normalize blood cell counts and…
Matched conditions: BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS
Phase: PHASE2 • Sponsor: William Shomali • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC